Literature DB >> 34252320

Key considerations in the pharmacological management of treatment-resistant depression.

Mani Yavi1, Ioline D Henter, Lawrence T Park, Carlos Zarate.   

Abstract

Introduction: Treatment-resistant depression (TRD) is a complex, multifactorial, and biologically heterogeneous disorder with debilitating outcomes. Understanding individual reasons why patients do not respond to treatment is necessary for improving clinical recommendations regarding medication regimens, augmentation strategies, and alternative treatments.Areas covered: This manuscript reviews evidence-based treatment strategies for the clinical management of TRD. Current developments in the field and potential future recommendations for personalized treatment of TRD are also discussed.Expert opinion: Treatment guidelines for TRD are limited by the heterogeneous nature of the disorder. Furthermore, current strategies reflect this heterogeneity by emphasizing disease characteristics as well as drug trial response or failure. Developing robust biomarkers that could one day be integrated into clinical practice has the potential to advance specific treatment targets and ultimately improve treatment and remission outcomes.

Entities:  

Keywords:  Augmentation; biomarkers; depression; guidelines; ketamine; management; treatment-resistant

Mesh:

Substances:

Year:  2021        PMID: 34252320      PMCID: PMC8648908          DOI: 10.1080/14656566.2021.1951225

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  123 in total

Review 1.  Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system.

Authors:  Carlos A Zarate; Jing Du; Jorge Quiroz; Neil A Gray; Kirk D Denicoff; Jaskaran Singh; Dennis S Charney; Husseini K Manji
Journal:  Ann N Y Acad Sci       Date:  2003-11       Impact factor: 5.691

2.  A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine.

Authors:  Linda L Carpenter; Sarah Yasmin; Lawrence H Price
Journal:  Biol Psychiatry       Date:  2002-01-15       Impact factor: 13.382

3.  Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

Authors:  A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Jonathan W Stewart; Andrew A Nierenberg; Michael E Thase; Louise Ritz; Melanie M Biggs; Diane Warden; James F Luther; Kathy Shores-Wilson; George Niederehe; Maurizio Fava
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245

4.  Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis.

Authors:  R Aronson; H J Offman; R T Joffe; C D Naylor
Journal:  Arch Gen Psychiatry       Date:  1996-09

Review 5.  Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants.

Authors:  Todd D Gould; Carlos A Zarate; Scott M Thompson
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-10-08       Impact factor: 13.820

6.  A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.

Authors:  Charles L Raison; Robin E Rutherford; Bobbi J Woolwine; Chen Shuo; Pamela Schettler; Daniel F Drake; Ebrahim Haroon; Andrew H Miller
Journal:  JAMA Psychiatry       Date:  2013-01       Impact factor: 21.596

Review 7.  Methylenetetrahydrofolate reductase and psychiatric diseases.

Authors:  Lin Wan; Yuhong Li; Zhengrong Zhang; Zuoli Sun; Yi He; Rena Li
Journal:  Transl Psychiatry       Date:  2018-11-05       Impact factor: 6.222

Review 8.  Prognosis and improved outcomes in major depression: a review.

Authors:  Christoph Kraus; Bashkim Kadriu; Rupert Lanzenberger; Carlos A Zarate; Siegfried Kasper
Journal:  Transl Psychiatry       Date:  2019-04-03       Impact factor: 6.222

9.  Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies.

Authors:  Maurizio Fava; Michael E Thase; Madhukar H Trivedi; Elliot Ehrich; William F Martin; Asli Memisoglu; Narinder Nangia; Arielle D Stanford; Miao Yu; Sanjeev Pathak
Journal:  Mol Psychiatry       Date:  2018-10-29       Impact factor: 15.992

Review 10.  S-Adenosylmethionine (SAMe) in major depressive disorder (MDD): a clinician-oriented systematic review.

Authors:  Alessandro Cuomo; Bruno Beccarini Crescenzi; Simone Bolognesi; Arianna Goracci; Despoina Koukouna; Rodolfo Rossi; Andrea Fagiolini
Journal:  Ann Gen Psychiatry       Date:  2020-09-05       Impact factor: 3.455

View more
  1 in total

Review 1.  Ketamine-New Possibilities in the Treatment of Depression: A Narrative Review.

Authors:  Mateusz Kowalczyk; Edward Kowalczyk; Paweł Kwiatkowski; Łukasz Łopusiewicz; Monika Sienkiewicz; Monika Talarowska
Journal:  Life (Basel)       Date:  2021-11-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.